DWA
REGN icon

Dorsey Wright & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Dorsey Wright & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,671
Closed -$2.06M – 375
2020
Q3 		$2.06M Buy
3,671
+53
+1% +$32.1K 0.37% 87
2020
Q2 		$2.26M Buy
+3,618
New +$2.05M 0.46% 74
2013
Q4 		– Sell
-10,504
Closed -$3.29M – 138
2013
Q3 		$3.29M Sell
10,504
-115
-1% -$30.2K 0.46% 26
2013
Q2 		$2.39M Buy
+10,619
New +$2.47M 0.39% 33

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Dorsey Wright & Associates's REGN Position: Q4 2020 in Review

Dorsey Wright & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 3,671 shares — an estimated $2.06M sold.

Dorsey Wright & Associates first reported a position in REGN in Q2 2013 and held it in 4 quarters. The position peaked at $3.29M in Q3 2013. 904 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Dorsey Wright & Associates reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3,671 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $2.06M.
  • Dorsey Wright & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Dorsey Wright & Associates's Regeneron Pharmaceuticals position peaked at $3.29M in Q3 2013.
  • 904 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Dorsey Wright & Associates's 13F filing for Q4 2020, filed 28 Jan 2021.